The gluten-free diet works—but it doesn’t work for everyone, and it doesn’t work perfectly even when followed strictly. A new review published in the World Journal of Gastrointestinal Pharmacology and Therapeutics examines why the diet falls short for many patients and explores emerging treatments that could supplement or even replace it.
The review, authored by gastroenterologists Sandeep K. Mundhra and Rakesh K. Kochhar, outlines three persistent problems with diet-only treatment: accidental gluten exposure happens despite careful efforts, long-term adherence proves difficult for many patients, and some people experience incomplete intestinal healing even when their symptoms improve and antibody levels normalize.
What This Means for You
For families like mine, this review validates what we already know from daily experience—the gluten-free diet is exhausting, and perfect adherence borders on impossible. My son can do everything right and still get glutened from cross-contact at a restaurant or a mislabeled product. The review acknowledges these real-world failures and argues that relying solely on diet leaves too many patients without adequate treatment.
The authors examine several categories of experimental therapies currently in development. Some work by breaking down gluten before it reaches the small intestine. Others target the immune response that causes intestinal damage. Still others aim to restore the intestinal barrier or modulate inflammation.
What makes this review particularly relevant is its focus on therapies that could work alongside the gluten-free diet—not as permission to eat gluten freely, but as a safety net for accidental exposure and a potential solution for patients who don’t heal completely on diet alone.
The review also highlights advances in monitoring beyond traditional antibody tests and symptoms. Newer biomarkers could detect ongoing intestinal damage earlier and more accurately, helping doctors identify patients who need additional treatment even when standard tests look normal.
Key Takeaways
- The gluten-free diet fails many patients through accidental exposure, adherence challenges, and incomplete healing.
- Multiple experimental therapies target different steps in celiac disease, from breaking down gluten to blocking immune responses.
- These treatments are being developed as supplements to the diet, not replacements for it.
- Better monitoring tools could identify patients who need treatment beyond diet alone.
- None of these therapies are approved yet—the gluten-free diet remains the only proven treatment.
The Science
Want to understand how these experimental treatments actually work and why researchers think they could help? We’ll walk you through the technical details below and define every term. No medical degree required.
Why the Gluten-Free Diet Isn’t Enough
The review identifies three specific limitations that affect real patients. First, inadvertent gluten exposure—accidental consumption through cross-contact, labeling errors, or hidden ingredients—triggers immune responses and intestinal damage even in highly vigilant patients. The threshold for harm is extremely low, measured in parts per million.
Second, long-term adherence presents practical and psychological barriers. The diet restricts social activities, increases food costs, and creates daily stress around meal planning and eating outside the home. Studies show that many patients, particularly adolescents and young adults, struggle to maintain strict adherence over years or decades.
Third, and perhaps most concerning, some patients show incomplete mucosal recovery—persistent intestinal damage visible on biopsy—despite following the diet strictly enough to achieve normal antibody levels and symptom relief. These patients appear well by standard measures but continue experiencing ongoing damage and elevated health risks.
Current Monitoring Limitations
Standard monitoring relies on symptoms and serology—blood tests measuring antibodies like tissue transglutaminase IgA (tTG-IgA). But symptoms correlate poorly with actual intestinal damage. Patients can feel fine while inflammation persists, or experience symptoms from other causes while their intestines heal.
The review discusses emerging biomarkers that could detect ongoing damage more accurately. These include intestinal fatty acid-binding protein (I-FABP), which spikes when intestinal cells are damaged, and specific immune markers that indicate active inflammation even when standard antibodies normalize.
Therapeutic Approaches Under Investigation
The authors categorize experimental therapies by their mechanism of action—how they intervene in the disease process.
Luminal enzymes work in the stomach or upper intestine to break down gluten before it reaches the sites where it triggers immune responses. We’ve previously covered enzyme therapies in detail. These include prolyl endopeptidases—enzymes that cut the specific chemical bonds in gluten that resist normal human digestion. The goal is to reduce the load of intact immunogenic peptides (protein fragments that trigger immune responses) reaching the small intestine.
Tight junction regulators aim to prevent intestinal permeability—the leaky barrier that allows gluten fragments to enter the tissue beneath the intestinal lining. A protein called zonulin controls the spaces between intestinal cells, and blocking it could maintain a tighter barrier even during gluten exposure.
Immune modulators target the specific immune responses that cause tissue damage. Some block tissue transglutaminase (tTG), the enzyme that modifies gluten fragments in ways that make them more recognizable to immune cells. Others target interleukin-15 (IL-15), an immune signaling molecule that drives the inflammatory response and activates the killer cells that destroy intestinal tissue.
Antigen-specific immunotherapy attempts to retrain the immune system to tolerate gluten through controlled exposure, similar to allergy shots. This includes therapies like NexVax2, which we’ve covered previously, though that specific candidate failed in late-stage trials.
HLA-DQ blockers target the specific molecules on immune cells that present gluten fragments to T cells. Celiac disease requires specific genetic variants (HLA-DQ2 or HLA-DQ8), and blocking these molecules could prevent the immune recognition that starts the cascade of damage.
The Path Forward
None of these therapies have gained regulatory approval. Most remain in early research stages, and several promising candidates have failed in clinical trials. The review emphasizes that all experimental approaches are designed to work with the gluten-free diet, not to enable unrestricted gluten consumption.
The authors argue for better monitoring tools to identify which patients need additional treatment and to measure whether new therapies actually prevent intestinal damage—not just improve symptoms or normalize antibodies.
A Celiac Parent’s Perspective
Reading reviews like this gives me cautious hope. My son follows the gluten-free diet meticulously, but I know he still gets exposed occasionally. The idea that we might someday have a safety net—an enzyme he could take before eating out, or a therapy that could block damage from accidental exposure—would fundamentally change our quality of life.
But I also recognize we’re years away from these options reaching pharmacy shelves. The research outlined in this review mostly describes early-stage concepts, not imminent treatments. For now, and for the foreseeable future, the gluten-free diet remains the only proven approach.
What this review does offer is validation that the scientific community recognizes the diet’s limitations and continues working on alternatives. It provides a comprehensive map of the therapeutic landscape—not just enzymes, but immune modulators, barrier protectors, and tolerance-inducing approaches. Each targets a different vulnerability in the disease process.
For families dealing with incomplete healing, persistent symptoms despite diet adherence, or the constant anxiety of accidental exposure, knowing that researchers are actively pursuing solutions provides some measure of reassurance. The gluten-free diet won’t be the only option forever.
Related Coverage
- Upcoming Treatments in Celiac Disease: From Luminal Enzymes to Oral Immune Tolerance
- Celiac Disease: A Comprehensive Review of Epidemiology, Pathogenesis, and Therapeutic Strategies
- Experimental drug offers new hope for celiac disease treatment - Medical Xpress
References
- Mundhra SK, Kochhar RK. Beyond gluten-free diet: Novel therapeutic frontiers in celiac disease armamentarium. World J Gastrointest Pharmacol Ther. 2026 Jun 5;17(2):114292. doi: 10.4292/wjgpt.v17.i2.114292. PMID: 42273246; PMCID: PMC13248124.